NEWS
Find a Professional: Explore Experts Across 197 Disciplines in 221 Countries!
Just Updated: Compare Your Institution (Live Data)
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025 (Updated Today)
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
Login
Register & Pricing
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
For Students
local_fire_department
Country Reports
person
Find a Professional
Chris Twelves
University of Leeds - Leeds / United Kingdom
Others
AD Scientific Index ID: 1192422
Registration, Add Profile,
Premium Membership
Get Your Global Impact Certificate
Ranking &
Analysis
Job
Experiences
Education
Information
Published Books
Book Chapters
Articles
Presentations
Lessons
Projects
Co-Authors
Subject Leaders
Editorship, Referee &
Scientific Board
Patents /
Designs
Academic Grants
& Awards
Artistic
Activities
Certificate / Course
/ Trainings
Association &
Society Memberships
Contact, Office
& Social Media
person_outline
Chris Twelves's MOST POPULAR ARTICLES
1-)
Capecitabine as adjuvant treatment for stage III colon cancer New England Journal of Medicine 352 (26), 2696-2704, 2005
2-)
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results Journal of clinical oncology 20 (12), 2812-2823, 2002
3-)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study The Lancet 377 (9769), 914-923, 2011
4-)
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study Journal of Clinical Oncology 19 (21), 4097-4106, 2001
5-)
Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 Journal of Clinical Oncology 36 (24), 2465-2472, 2018
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept